This improved deployment of antitumor immunity was seen together with a markedly lower Treg presence in the tumor microenvironment, findings also observed on Treg-specific YAP deficiency across other distinct tumor models [38] (Figure 1). The gene discussed is YAP1; the disease is neoplasm.